Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ultra-high Yield Intravenous Immune Globulin Preparation

a technology of immune globulin and intravenous injection, which is applied in the direction of extracellular fluid disorder, drug composition, peptide, etc., can solve the problems of permanent denaturation, increase in temperature, and increase in denaturation danger, and achieves rapid infused, high yield, and greater patient tolerance

Inactive Publication Date: 2008-10-02
PLASMA TECH LLC
View PDF15 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]Also, addition of these salts to protein in solution proves to be not as reactive to removal of water as addition of ethanol by previous methods. A rapid isolation using these salts, removal of the resulting fraction followed by removal of salt from the resulting fraction and a quick restoration of the internal water molecule of the protein has proved superior to ethanol fractionation using currently employed methods.
[0037]It is an object to produce gamma globulin having reduced in-process formation of polymers, aggregates, fragments, enzyme activators and proteolytic enzymes compared with similar preparations produced using traditional alcohol-based methods.

Problems solved by technology

Even so, the use of alcohol precipitants is not without difficulties, as illustrated by Cohn, “Some protein precipitants, such as alcohol, have a tendency to denature many proteins with which they come in contact, the danger of denaturation increasing with concentration of the alcohol and increase in temperature.
Such binding may be a cause of changes in protein configuration resulting in some permanent denaturation of protein molecules which remains after ethanol is removed and water is returned.
However, chromatographic separation of the large-weight, lower-value fractions such as albumin and gamma globulin, on an industrial scale has not been found to be practical.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ultra-high Yield Intravenous Immune Globulin Preparation
  • Ultra-high Yield Intravenous Immune Globulin Preparation
  • Ultra-high Yield Intravenous Immune Globulin Preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0044]Reference is now made to flow path elements illustrated in FIGS. 1-4. Generally, each rectangular box is used to illustrate a procedural step; each diamond is used to demonstrate a separation step; each elliptical cylinder designates a product resulting from a preceding procedural or separation step; and each circle is used to identify either a starting point or an off sheet continuation path point.

[0045]Reference is now made to FIG. 1 wherein an initial portion 10-1 of an preferred IgG process flow path, generally numbered 10, is seen. As indicated after initial starting point 20, a volume of plasma 30 to be processed is selected for processing. It should be noted that while plasma 30 is used by example in this description of an illustrated embodiment, other blood-based products may be processed within the scope of the instant invention. Also, after preparation for use, a separation step 42 is used to separate a paste 44 from prepared cryo-poor plasma 50, as is disclosed in m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
pHaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs one or more salts from a group of salts comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride in two initial fractionation steps, followed by diafiltration to remove those salts employed. A process which employs alcohol via the process of the disclosed inventive method is also disclosed.

Description

[0001]This Application for Patent is a Divisional of U.S. patent application Ser. No. 11 / 358,431, filed Feb. 21, 2006, which is a Continuation-in-Part of U.S. patent application Ser. No. 11 / 232,527, filed Sep. 22, 2005, which is a Continuation-in-Part of U.S. patent application Ser. No. 11 / 217,956, filed Sep. 1, 2005.FIELD OF INVENTION[0002]This invention relates generally to methods for immune serum globulin purification, and, more particularly, to methods for alcohol-free separation of immune globulin from blood plasma or other blood based material. Interestingly, the method of the instant invention also may be employed using alcohol.BACKGROUND AND DESCRIPTION OF RELATED ART[0003]Commonly, contemporary methods for separation of immune globulins (IgG) from blood plasma or other blood based material depend upon early work by Edwin J. Cohn. As found in U.S. Pat. No. 5,177,194 issued Jan. 5, 1993 to Maria E. Samo, et al. (SARNO), “One scheme in widespread use is the well-known Cohn fr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/18
CPCC07K14/765A61P7/00
Inventor ZURLO, GENECURTIN, DENNISLOUDERBACK, ALLAN L.
Owner PLASMA TECH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products